Blood group tests
ABO and RhD grouping, the antibody screen, electronic, immediate-spin and IAT crossmatches, sample validity under the ANZSBT 2025 guidelines, emergency group O issue, and interference from daratumumab and other monoclonal antibodies.
Tier 2Medical sciences concept
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- A group and screen is ABO and RhD grouping plus an antibody screen. It is the standard pretransfusion test. A crossmatch then confirms a particular unit is compatible.
- Most patients have no antibodies and get blood by electronic crossmatch in minutes. An antibody means antigen-negative units and an IAT crossmatch, which takes hours.
- Under ANZSBT 2025 a sample lasts 72 hours if the patient was transfused or pregnant in the past 3 months, and up to 3 months if not.
Loading the rest of the note…
Finished reading?
Sources
- Guidelines for transfusion and immunohaematology laboratory practice, 2nd editionAU/NZAustralian and New Zealand Society of Blood Transfusion (ANZSBT), June 2025, revised September 2026
- Blood typesAU/NZAustralian Red Cross Lifeblood, 2019 data
- Patient blood management guideline for adults with critical bleedingAU/NZNational Blood Authority, 2023, updated 2025
- Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myelomaAU/NZQuach H et al., Intern Med J 2018;48:210-20, 2018
- Component compatibilityAU/NZAustralian Red Cross Lifeblood
- Sallman DA et al. Magrolimab plus azacitidine versus placebo plus azacitidine in untreated higher-risk myelodysplastic syndromes: the phase III ENHANCE study. J Clin Oncol 2026;44:2529-42Journal of Clinical Oncology, 2026
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback